Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make the pancreatic cancer treatment Lynparza available to NHS patients.

This question was answered on 29th March 2022

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service in England on whether new medicines represent a clinically and cost-effective use of resources.

NICE has been unable to make a recommendation on the use of Lynparza (olaparib) for the maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy as the company did not make an evidence submission. Olaprarib is not therefore currently routinely funded by the NHS in England for pancreatic cancer. NICE will review this decision should the company make a submission.